AzurRx BioPharma Inc. appointed James Pennington to the position of chief medical officer.
Pennington's appointment comes as the biotechnology company prepares to initiate a phase 2 clinical study of its drug MS1819 in cystic fibrosis and file an investigational drug application for the therapy in the U.S.
Pennington served as vice president at Bayer Corp., a unit of Bayer AG.
New York-based AzurRx BioPharma develops therapies to treat gastrointestinal diseases and infectious diseases.
